New ‘Dark Genome’ Biotech Gets Backing From Big Pharma Venture Funds
Autoimmune Diseases Will Be First Target
The Oxford University spin-out has raised $37.5m in a series A thanks to its technology which pinpoints the link between genes and diseases and maps pathways for drug discovery.
